Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof

A crystalline form of a compound comprising

• wherein the crystalline form is characterized by an X-ray powder diffraction pattern selected from the group consisting of:
• (a) an X-ray powder diffraction pattern having the characteristic peaks expressed in values of degrees 2-theta at approximately 7.5, 9.9, 12.4, 14.3, 15.1, 15.9, 16.6, 18.1, 20.0, 21.2, 24.8, and 25.5;
• (b) an X-ray powder diffraction pattern having the characteristic peaks expressed in values of degrees 2-theta at approximately 9.0, 12.6, 13.7, 16.6, 18.1, 18.4, 19.4, 19.7, 20.2, 20.8, 22.5, and 23.0;
• (c) an X-ray powder diffraction pattern having the characteristic peaks expressed in values of degrees 2-theta at approximately 7.8, 9.4, 12.3, 13.6, 15.2, 15.8, 18.2, 19.7, 20.8, 21.6, 22.6, 26.3, and 26.9;
• (d) an X-ray powder diffraction pattern having the characteristic peaks expressed in values of degrees 2-theta at approximately 9.7, 12.4, 14.1, 15.2, 15.7, 16.7, 17.8, 18.1, 19.7, 21.1, 25.0, 23.3, 28.9, and 29.4;
• (e) an X-ray powder diffraction pattern having the characteristic peaks expressed in values of degrees 2-theta at approximately 7.4, 9.8, 12.3, 14.1, 14.9, 15.8, 16.4, 17.9, 18.1, 20.0, 21.1, 22.5, 24.5, 25.3, and 29.2;
• and
• (f) an X-ray powder diffraction pattern having the characteristic peaks expressed in values of degrees 2-theta at approximately 12.8, 14.2, 17.0, 17.7, 18.6, 20.8, 21.2, 22.2, 23.6, 25.3, and 28.4.